These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 39372417)

  • 41. Microbiota-Driven Activation of Intrahepatic B Cells Aggravates NASH Through Innate and Adaptive Signaling.
    Barrow F; Khan S; Fredrickson G; Wang H; Dietsche K; Parthiban P; Robert S; Kaiser T; Winer S; Herman A; Adeyi O; Mouzaki M; Khoruts A; Hogquist KA; Staley C; Winer DA; Revelo XS
    Hepatology; 2021 Aug; 74(2):704-722. PubMed ID: 33609303
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications.
    Targher G; Byrne CD; Tilg H
    Gut; 2024 Mar; 73(4):691-702. PubMed ID: 38228377
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice.
    Ilagan-Ying YC; Banini BA; Do A; Lam R; Lim JK
    Curr Gastroenterol Rep; 2023 Oct; 25(10):213-224. PubMed ID: 37768417
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Polyzos SA; Targher G
    Curr Obes Rep; 2024 Jun; 13(2):242-255. PubMed ID: 38459229
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Suppression of STK39 weakens the MASLD/MASH process by protecting the intestinal barrier.
    Xu Q; Liu F; Wu Z; Chen M; Zhou Y; Shi Y
    Biosci Trends; 2024 Jul; 18(3):289-302. PubMed ID: 38925962
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CD44 is a key player in non-alcoholic steatohepatitis.
    Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
    J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Increased hepatic putrescine levels as a new potential factor related to the progression of metabolic dysfunction-associated steatotic liver disease.
    Núñez-Sánchez MÁ; Martínez-Sánchez MA; Sierra-Cruz M; Lambertos A; Rico-Chazarra S; Oliva-Bolarín A; Balaguer-Román A; Yuste JE; Martínez CM; Mika A; Frutos MD; Llamoza-Torres CJ; Córdoba-Chacón J; Ramos-Molina B
    J Pathol; 2024 Sep; 264(1):101-111. PubMed ID: 39022853
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Liver Cell Mitophagy in Metabolic Dysfunction-Associated Steatotic Liver Disease and Liver Fibrosis.
    Chen J; Jian L; Guo Y; Tang C; Huang Z; Gao J
    Antioxidants (Basel); 2024 Jun; 13(6):. PubMed ID: 38929168
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chitinase 1: a novel therapeutic target in metabolic dysfunction-associated steatohepatitis.
    Cha JH; Park NR; Cho SW; Nam H; Yang H; Jung ES; Jang JW; Choi JY; Yoon SK; Sung PS; Bae SH
    Front Immunol; 2024; 15():1444100. PubMed ID: 39381000
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Crosstalk Between Liver Macrophages and Surrounding Cells in Nonalcoholic Steatohepatitis.
    Li H; Zhou Y; Wang H; Zhang M; Qiu P; Zhang M; Zhang R; Zhao Q; Liu J
    Front Immunol; 2020; 11():1169. PubMed ID: 32670278
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Endoscopic sleeve gastroplasty for metabolic dysfunction-associated steatotic liver disease.
    Matteo MV; Gualtieri L; Bove V; Palumbo G; Pontecorvi V; De Siena M; Barbaro F; Spada C; Boškoski I
    Expert Rev Gastroenterol Hepatol; 2024 Aug; 18(8):397-405. PubMed ID: 39234763
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The double roles of T cell-mediated immune response in the progression of MASLD.
    Li Z; Wang S; Xu Q; Su X; Wang Y; Wang L; Zhang Y
    Biomed Pharmacother; 2024 Apr; 173():116333. PubMed ID: 38479177
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hepatic angiotensin-converting enzyme 2 expression in metabolic dysfunction-associated steatotic liver disease and in patients with fatal COVID-19.
    Jacobs AK; Morley SD; Samuel K; Morgan K; Boswell L; Kendall TJ; Dorward DA; Fallowfield JA; Hayes PC; Plevris JN
    World J Gastroenterol; 2024 Aug; 30(31):3705-3716. PubMed ID: 39192998
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hepatic danger signaling triggers TREM2
    Zhou L; Qiu X; Meng Z; Liu T; Chen Z; Zhang P; Kuang H; Pan T; Lu Y; Qi L; Olson DP; Xu XZS; Chen YE; Li S; Lin JD
    Sci Transl Med; 2024 Mar; 16(738):eadk1866. PubMed ID: 38478630
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The "Domino effect" in MASLD: The inflammatory cascade of steatohepatitis.
    Mladenić K; Lenartić M; Marinović S; Polić B; Wensveen FM
    Eur J Immunol; 2024 Apr; 54(4):e2149641. PubMed ID: 38314819
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phytonanotherapy for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Nendouvhada LP; Sibuyi NRS; Fadaka AO; Meyer S; Madiehe AM; Meyer M; Gabuza KB
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891759
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease.
    Marti-Aguado D; Calleja JL; Vilar-Gomez E; Iruzubieta P; Rodríguez-Duque JC; Del Barrio M; Puchades L; Rivera-Esteban J; Perelló C; Puente A; Gomez-Medina C; Escudero-García D; Serra MA; Bataller R; Crespo J; Arias-Loste MT
    J Hepatol; 2024 Jul; ():. PubMed ID: 38971533
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting PYK2 with heterobifunctional T6BP helps mitigate MASLD and MASH-HCC progression.
    Xu M; Zhao J; Zhu L; Ge C; Sun Y; Wang R; Li Y; Dai X; Kuang Q; Hu L; Luo J; Kuang G; Ren Y; Wang B; Tan J; Shi S
    J Hepatol; 2024 Sep; ():. PubMed ID: 39260704
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BRUCE liver-deficiency potentiates MASLD/MASH in PTEN liver-deficient background by impairment of mitochondrial metabolism in hepatocytes and activation of STAT3 signaling in hepatic stellate cells.
    Che L; Stevenson CK; Plas DR; Wang J; Du C
    bioRxiv; 2024 Sep; ():. PubMed ID: 39314445
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
    Staufer K; Stauber RE
    Biomedicines; 2023 Jul; 11(8):. PubMed ID: 37626604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.